Short Interest in Synthetic Biologics, Inc. (SYN) Drops By 12.6%

Synthetic Biologics, Inc. (NYSEAMERICAN:SYN) was the recipient of a large drop in short interest in November. As of November 15th, there was short interest totalling 6,268,579 shares, a drop of 12.6% from the October 31st total of 7,176,264 shares. Based on an average trading volume of 909,188 shares, the short-interest ratio is presently 6.9 days. Approximately 5.5% of the shares of the stock are short sold.

Shares of Synthetic Biologics (NYSEAMERICAN SYN) opened at $0.66 on Friday. Synthetic Biologics has a 1-year low of $0.41 and a 1-year high of $1.05.

Synthetic Biologics (NYSEAMERICAN:SYN) last announced its quarterly earnings data on Wednesday, November 1st. The company reported ($0.14) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.04) by ($0.10).

Several analysts have weighed in on the company. Zacks Investment Research raised Synthetic Biologics from a “hold” rating to a “buy” rating and set a $0.75 price target on the stock in a report on Wednesday, August 9th. ValuEngine raised Synthetic Biologics from a “strong sell” rating to a “sell” rating in a report on Friday, August 18th. Finally, BidaskClub cut Synthetic Biologics from a “hold” rating to a “sell” rating in a report on Saturday, November 4th. Two analysts have rated the stock with a sell rating, one has given a hold rating and two have issued a buy rating to the company. The company presently has a consensus rating of “Hold” and a consensus price target of $3.92.

ILLEGAL ACTIVITY WARNING: “Short Interest in Synthetic Biologics, Inc. (SYN) Drops By 12.6%” was first posted by Sports Perspectives and is the sole property of of Sports Perspectives. If you are viewing this news story on another publication, it was illegally stolen and reposted in violation of US and international copyright and trademark law. The correct version of this news story can be viewed at

About Synthetic Biologics

Synthetic Biologics, Inc is a clinical-stage company. The Company is engaged in developing therapeutics to protect the gut microbiome while targeting pathogen-specific diseases. The Company’s lead product candidates in Phase II development are SYN-010, which is intended to reduce the impact of methane-producing organisms in the gut microbiome to treat an underlying cause of irritable bowel syndrome with constipation (IBS-C), and SYN-004, which is designed to protect the gut microbiome (gastrointestinal (GI) microflora) from the effects of certain commonly used intravenous (IV) antibiotics for the prevention of C.

Receive News & Ratings for Synthetic Biologics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synthetic Biologics Inc. and related companies with's FREE daily email newsletter.

Latest News

Leave a Reply